Investigation of Glucocorticoid Receptor Degradation and Its Antagonists to Address Cancer Drug Resistance
CSEF · 2016 Biochemistry/ Molecular Biology
Overview
Objectives/Goals Prostate cancer treatment relies upon suppression of the androgen receptor (AR) pathway, but high levels of glucocorticoid receptor (GR) compensates for loss of AR activity, resulting in a drug-resistant tumor. Similarly, the default treatment method of chemotherapy for triple-negative breast cancer is only temporarily successful in the presence of high GR expression. To address the prevalent problem of cancer relapse, this project develops methods to lower GR level and identify suitable compounds to restore drug sensitivity and therapy effectiveness for prostate and breast cancer tumor-combative treatment. Methods/Materials A stable cell line was developed to evaluate compounds that can degrade GR. The cell line was transfected with a plasmid construct designed to express the GR linked to a fluorescent indicator. Protein expression and GR functionality were also tested with Western Blot and fluorescence microscope. A pharmacophore query was established by analyzing features of a known GR antagonist complex to mine a compound database. Results The stable cell line transfected with the plasmid was successfully created and in the presence of GR agonists, cell colonies express fluorescence concentration in the nucleus, indicating correct GR functionality. Molecular modeling identified 29 potential antagonists. Conclusions/Discussion The cell line has capability for high through-put screening of future GR antagonists, and compounds that degrade GR will be identifiable by loss of fluorescence. Multiple compounds were identified through modeling search for GR antagonists and five are promising for future testingon the stable cell line. The discovery and usage of these GR-degradative compounds has important implications for GR-directed cancer therapy to prevent drug resistance.
Summary statement
Applying a glucocorticoid receptor (GR)-directed approach, I developed a stable cell line to evaluate GR level and identified potential GR antagonists with molecular modeling to address drug resistance in breast and prostate cancer.
Help received
Laboratory experiments were carried out independently using equipment and facilities in the Dr. Ronald M. Evans Lab at the Salk Institute under the mentorship of Dr. Nanhai He. Molecular modeling procedures were designed and implemented by myself.
Competition history
- CSEF 2016
Resources
Related projects
CSEF · 2009
Mechanisms of Survival Against a Fatty Acid Synthase Inhibitor in Multidrug Resistant Ovarian Cancer
CSEF · 2008
The Effects of a Fatty Acid Synthase Inhibitor on Multi-drug Resistant Ovarian Cancer Cells
CSEF · 2018
Identifying the Mechanisms of Liver Cancer Cell Drug Resistance
ISEF · 2026
Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
ISEF · 2020
Examining Mechanisms of Resistance in Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells
CSEF · 2017
Designing an Innovative Multi-Faceted Smart Drug for Lung Cancer: Revolutionizing Targeted Cancer Treatment
CSEF · 2017
Efficacy of BIBR1532 in Combination with Nutrient Deprivation on Reduction of Cell Viability in MCF7 and HT1080
CSEF · 2010
Multi-Drug Resistance and the Mechanism of Orlistat-Induced Cell Death in Ovarian Carcinoma
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects